Insufficient sleep has been hypothesised to increase the breast cancer risk ([@bib1]). Mechanistic studies have shown that short sleep duration (\<6 h) may lead to obesity ([@bib14]), metabolic dysfunction ([@bib5]), chronic inflammation ([@bib7]), and altered oestrogen signalling due to suppressed melatonin production ([@bib13]), suggesting that an effect of sleep on breast cancer development is biologically plausible. Several epidemiological studies, including five cohort studies and two case control studies, have examined the relationship between sleep duration and breast cancer risk and produced mixed results, reporting inverse ([@bib15]; [@bib8]), positive ([@bib10]), and null ([@bib11]; [@bib6]; [@bib16]; [@bib17]) associations.

Breast cancer subtypes, classified by the expression of oestrogen receptor (ER) and progesterone receptor (PR), possess distinct biological, aetiological and clinical characteristics ([@bib2]). There has been limited work evaluating the effects of sleep duration on risks of different subtypes of breast cancer ([@bib6]; [@bib16]), and no study has examined the association by PR status. In the Breast Cancer Detection Demonstration Project (BCDDP) follow-up study, we prospectively investigated sleep duration in relation to overall breast cancer risk and risks for different tumour subtypes defined by ER and PR status.

Materials and methods
=====================

Study population
----------------

The details of the BCDDP study have been described before ([@bib4]). Briefly, between 1973 and 1980, 283 222 women were enrolled in the original study, and in 1979, the BCDDP follow-up study was established, and 61 431 women completed the baseline questionnaire. In 1987--1989, 1993--1995 and 1995--1998, participants filled three additional questionnaires, which collected information on additional risk factors and self-reported cancer diagnosis. Information on sleep duration was collected in the phase 2 questionnaire (1987--1989). Of the 51 690 who completed the phase 2 questionnaire, we further excluded those who reported existing cancer (*N*=7766), and who did not report sleep duration (*N*=3911). The final analytic cohort included 40 013 women.

Breast cancer ascertainment
---------------------------

New incident breast cancer cases were identified through pathology reports, self-reports, as well as linkage to state cancer registries and the National Death Index. Pathology reports were sought for all self-reported cancers. In addition, about 80% of the cohort was linked to state cancer registries. Of 1846 breast cancer cases, 1358 had matching pathology reports, 279 were ascertained from state cancer registries alone without pathology reports and 209 were self-reported breast cancers with no pathology report or information from a state registry. Excluding the 209 cases that were based on self-report alone had a minimal impact on the results and we retained these cases in analysis. The status of ER and PR was obtained from cancer registries. The ER status was available for 1093 breast cancer cases and the PR status was available for 1000 breast cancer cases.

Assessment of sleep duration
----------------------------

Participants reported their sleep duration on weekdays and weekends separately by responding to the question 'Thinking about a typical weekday and weekend day during the past year, how many hours per day did you spend on sleeping?\' We calculated weighted average of sleep duration per 24 h ((weekday sleep duration × 5+weekend sleep duration × 2)/7). Weekday, weekend and average sleep duration were grouped into five categories: \<6 h, 6 -- \<7 h, 7 -- \<8 h, 8 -- \<9 h and ≥9 h. We used the largest group, 8 -- \<9 h, as the reference.

Statistical analysis
--------------------

We used Cox proportional hazards regression models to estimate relative risks (RRs) and 95% confidence intervals (CIs) for both overall breast cancer and subtypes of breast cancer defined by ER and PR status. Person-years of follow-up time were calculated from baseline until the date of primary cancer diagnosis, death, or the end of follow-up (31 December 2005), whichever came first. Model covariates were potential risk factors for breast cancer, including age, race, education, marital status, body-mass index (BMI), physical activity, current smoking status and pack-years smoked, number of live births, age at first birth, age at menarche, menopausal status, use of hormonal replacement therapy, use of multivitamin, use of aspirin, history of diabetes, family history of breast cancer and alcohol consumption. All the covariates were assessed at baseline. Tests for linear trend were performed by modelling a numeric value (1 through 5) for each sleep category. To evaluate the potential impact of reverse causation, we excluded cases diagnosed within 2 years after baseline in a sensitivity analysis. We also performed a sensitivity analysis by restricting to postmenopausal women. Additionally, we tested for interactions between sleep duration and age, education and BMI using the likelihood ratio test comparing a model with the cross-product term with one without. All analyses were performed using SAS program (SAS 9.3; SAS Institute, Cary, NC, USA).

Results
=======

At baseline, 40.1% women reported 8 to less than 9 h of sleep in weekdays, 10.3% reported 9 h or longer, while only 4.1% reported less than 6 h. Study characteristics by weekday sleep duration are presented in [Table 1](#tbl1){ref-type="table"}.

We did not observe an association of overall breast cancer risk with weekday, weekend or averaged sleep duration ([Table 2](#tbl2){ref-type="table"}). Adjusting for multiple covariates had little impact on the findings. The results remained null after we excluded the cases diagnosed within 2 years of follow-up, or restricting analysis to postmenopausal women (data not shown).

We examined the relationship between sleep duration and risks of subtypes of breast cancer ([Table 3](#tbl3){ref-type="table"}). Shorter sleep duration during weekdays was associated with reduced risks of ER+ (RR ~\<6 h\ *vs*\ 8 -- \<9 h~ (95% CI, *P* for trend): 0.53 (0.33, 0.86), 0.001), PR+ (0.62 (0.38, 1.02), 0.003) and ER+PR+ breast cancer (0.54 (0.31, 0.93), 0.003). In contrast, we observed an elevated risk of ER− (2.12 (1.18, 3.82)) and ER−PR− subtypes (2.07 (1.07, 4.02)) among women reporting \<6 h sleep, although the trend for associations was not statistically significant. Similar results are observed for weekend sleep duration ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}) and the average of weekday and weekend sleep ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). We found no interaction between sleep and age, education, race, BMI or use of menopausal hormone therapy in relation to breast cancer risk (data not shown).

Discussion
==========

In this cohort of predominantly postmenopausal women, we found no association between sleep duration and overall breast cancer risk. Our findings for subtypes of breast cancer suggested a decreased risk of ER- and PR-positive breast cancer and an increased risk of ER-negative breast cancer among women who reported \<6 h of sleep.

Previous studies on sleep duration and overall breast cancer risk generally reported weak or null associations. Although some earlier investigations found an inverse relationship ([@bib15]; [@bib8]), a similar association has not been observed in the more recent, larger studies. The two largest prospective studies on this topic conducted in the Nurses\' Health Study (NHS) ([@bib11]) and the Women\'s Health Initiative (WHI) ([@bib16]), both found no association between sleep duration and overall breast cancer risk. Moreover, two recent meta-analyses reported no evidence for an effect of sleep duration on overall breast cancer risk ([@bib12]; [@bib18]).

Our findings of different effects of short sleep duration on different hormone receptor subtypes of breast cancer are intriguing, although the results may be due to chance alone and need to be confirmed by future studies. Only two studies examined sleep duration and breast cancer risk by ER status. A case--control study in Australia reported that sleep duration on workday or non-workday was not associated with either ER+ or ER− breast cancer ([@bib6]). In the WHI study, no association between sleep duration and ER− tumour was observed. However, a weak trend of positive association (*P*=0.02) with ER+ tumour was noted, although risk estimates were not significant for the individual sleep categories (RR ~⩽5 h\ *vs*\ 7 h~ (95% CI): 0.92 (0.80, 1.05)) ([@bib16]).

According to the melatonin hypothesis, sleep deficiency and circadian disruption reduce the level of melatonin, a hormone that modulates both oestrogen metabolism and ER-mediated signalling pathway and is considered to have an anticarcinogenic effect against breast cancer ([@bib3]). Therefore, short sleep has been hypothesised to increase the risk of ER+ breast cancer. We found no support for this hypothesis and if anything, we observed a reduced risk of ER+ breast cancer among women who reported short sleep. In contrast, we found an elevated risk of ER− breast cancer among short sleepers, which suggests the possibility of oestrogen-independent effects of short sleep on breast cancer risk. Circadian clock regulates a wide range of physiological functions, including energy metabolism, immune activity, DNA repair and cell proliferation ([@bib1]). Insufficient sleep as a form of circadian disruption may impact breast cancer risk through its influence on these pathways. Future studies are needed to identify biological mechanisms that may link sleep and circadian disturbances with cancer.

One of the limitations of this study is that sleep duration was self-reported and prone to measurement error. Previous studies showed that self-reported and measured sleep duration are only moderately correlated and people with short sleep are more likely to over-report their sleep duration than are people with longer sleep ([@bib9]). This would lead to misclassification of the main exposure and may result in an attenuation of observed associations for the short sleep categories. Additionally, we only had one-time measurement of sleep, and were not able to capture change in in sleep duration and evaluate its effect on breast cancer risk. We also lacked information on other important aspects of sleep that may influence breast cancer risk, such as sleep quality, snoring, sleep disorder, sleeping pill use, chronotype, napping habit and light at night. Moreover, we did not have information on occupational history, and night shift work might confound the observed associations. Finally, we had small number of cases of ER− and PR− tumours, and therefore we have limited statistical power in our analysis of these subtypes. There are several notable strengths of this study. Its prospective design decreases the likelihood of differential recall bias, a serious limitation of case--control studies. Additionally, the large cohort with a fairly long follow-up time allowed us to conduct a sensitivity analysis by excluding cases diagnosed with the first 2 years, reducing the possibility for reverse causation due to undiagnosed breast cancer.

In summary, our finding does not support an association between sleep duration and overall breast cancer risk. However, the effect of sleep on different subtypes of breast cancer deserves further investigation.

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
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###### 
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###### Baseline characteristics of 40 013 women in the Breast Cancer Detection Demonstration Project, 1987--1989

                                             **Weekday sleep duration, hour**                                                
  ----------------------------------------- ---------------------------------- ------------- --------------- --------------- -------------
  *N* (%)                                               1634 (4.1)              6714 (16.8)   11 529 (28.8)   16 032 (40.1)   4104 (10.3)
  Age, year, mean (s.d.)                                62.9 (8.9)              61.2 (8.0)     60.5 (7.5)      62.2 (8.0)     64.3 (8.9)
  BMI, kg m^−2^, mean (s.d.)                            25.6 (5.0)              25.2 (4.7)     24.8 (4.4)      25.1 (4.5)     25.6 (5.0)
  White, non-Hispanic, %                                   70.4                    82.3           89.2            91.9           90.2
  College or post-college, %                               16.9                    22.2           24.1            21.6           19.2
  Married, %                                               76.6                    80.8           84.3            84.9           82.2
  Family history of cancer, %                              32.1                    31.7           33.2            33.7           32.9
  Current smoker, %                                        13.5                    13.9           12.5            12.2           10.7
  Nulliparous, %                                           15.0                    14.1           12.4            13.2           13.8
  Age at first live birth, ≥30 years, %                    9.6                      8.7            8.7             8.7            8.2
  Age at menarche ⩽12, %                                   45.0                    44.9           43.5            42.0           40.3
  Post-menopausal, %                                       95.4                    92.9           91.2            92.8           94.4
  HRT use, %                                               54.3                    56.4           57.8            58.4           60.1
  Diabetes, %                                              7.6                      4.7            3.9             4.2            7.4
  Vigorous activity, 2+ hours per day, %                   19.7                    23.7           21.8            21.7            16
  Multivitamin use, %                                      33.4                    35.2           35.7            35.4           34.9
  Alcohol consumption, 15+ g per day, %                    5.9                      7.7            9.5            11.3           10.8
  **Dietary intakes, mean (s.d.)**                                                                                           
  Total calories, kcal                                  1180 (727)              1236 (731)     1276 (731)      1293 (723)     1338 (903)
  Total fat, g kcal^−1^                                37.2 (10.2)              38.4 (10.0)    38.8 (9.6)      38.8 (9.7)     39.2 (10.1)
  Total fiber, g kcal^−1^                               9.8 (4.9)                9.5 (4.1)      9.4 (3.9)       9.4 (3.9)      9.1 (3.9)
  Total fruits and vegetables, g kcal^−1^               390 (276)                361 (216)      355 (202)       353 (206)      337 (207)

Abbreviations: BMI=body mass index; HRT=hormone replacement therapy; s.d.=standard deviation.

###### Association between baseline sleep duration and breast cancer risk among women in the Breast Cancer Detection Demonstration Project

                                                                                        **Sleep duration, hour**                                                                            
  ------------------------------------------------------------------------------------ -------------------------- ------------------- ------------------- ------------- ------------------- --------
  **Weekday**                                                                                                                                                                               
  No. of cases/person-years                                                                    69/13 261              326/55 270          496/95 496       769/131 471      186/32 660       
  RR (95% CI)                                                                                                                                                                                
   Age adjusted                                                                            0.88 (0.69, 1.13)       1.02 (0.90, 1.16)   0.91 (0.81, 1.01)       Ref       0.95 (0.81, 1.12)  *0.71*
   Multivariate adjusted[a](#t2-fn2){ref-type="fn"}                                        0.90 (0.70, 1.16)       1.04 (0.91, 1.18)   0.91 (0.81, 1.02)       Ref       0.95 (0.80, 1.11)  *0.95*
  **Weekend**                                                                                                                                                                               
  No. of cases/person-years                                                                     44/8820               176/33 022          357/68 452       809/138 171      327/56 268       
  RR (95% CI)                                                                                                                                                                                
   Age adjusted                                                                            0.82 (0.61, 1.11)       0.90 (0.76, 1.05)   0.89 (0.79, 1.01)       Ref       0.99 (0.87, 1.13)  *0.04*
   Multivariate adjusted                                                                   0.86 (0.63, 1.17)       0.92 (0.78, 1.08)   0.91 (0.80, 1.03)       Ref       0.99 (0.87, 1.12)  *0.12*
  **Weighted average**                                                                                                                                                                      
  No. of cases/person-years                                                                     45/9167               267/45 524          449/85 072       631/108 873      161/27 081       
  RR (95% CI)                                                                                                                                                                                
   Age adjusted                                                                            0.85 (0.63, 1.15)       1.03 (0.89, 1.19)   0.93 (0.82, 1.05)       Ref       1.00 (0.84, 1.19)  *0.58*
   Multivariate adjusted                                                                   0.87 (0.64, 1.18)       1.04 (0.90, 1.20)   0.93 (0.82, 1.05)       Ref       1.00 (0.84, 1.19)  *0.71*
  **Weekday sleep, excluding cases diagnosed within the first 2 years of follow-up**                                                                                                        
  No. of cases/person-years                                                                    57/13 244              257/55 162          402/95 384       624/131 279      149/32 600       
  RR (95% CI)                                                                                                                                                                                
   Age adjusted                                                                            0.90 (0.69, 1.18)       0.99 (0.86, 1.14)   0.90 (0.79, 1.02)       Ref       0.95 (0.79, 1.13)  *0.59*
   Multivariate adjusted                                                                   0.93 (0.70, 1.22)       1.01 (0.87, 1.17)   0.90 (0.80, 1.03)       Ref       0.95 (0.79, 1.13)  *0.80*

Abbreviations: CI=confidence interval; RR=relative risk.

Adjusted for age (continuous), race (black, white, other), education (less than high school, high school graduate, some college, college or higher), marital status (married, unmarried), body-mass index (\<18.5, 18.5 -- 24.9, 25 -- 29.9, 30+ kg m^−2^), vigorous physical activity (\<1, 1 -- \<2, 2+ hours per day), smoking status (former, current, never smoker), pack-year (0, \>0 -- 20, \>20 -- 40, \>40), year since quitting (never smoker, current smoker, 0.5 -- 4, 5 -- 9, 10+ years), age at first live birth (\<20, 20 -- 29, 30+ years), number of live birth (0, 1 -- 2, 2+), age at first birth (age at menarche (12 or younger, older than 12)), menopause (yes, no), use of hormonal replacement therapy (yes, no), use of multivitamin (yes, no), history of diabetes (yes, no), family history of cancer (no history, breast or ovarian cancer, other cancer) and alcohol consumption (never drinker, 0 -- 6, 7 -- 15, 16+g per day).

###### Association between baseline weekday sleep duration and breast cancer risk among women in the Breast Cancer Detection Demonstration Project, by hormonal receptor status of breast cancer

                                                         **Weekday sleep duration, hour**                                                                            
  ----------------------------------------------------- ---------------------------------- ------------------- ------------------- ------------- ------------------- -------
  **ER+**                                                                                                                                                            
  No. of cases/person-years                                         18/13 106                  124/54 537          221/94 491       378/130 102       98/32 387       
  Multivariate RR[a](#t3-fn2){ref-type="fn"} (95% CI)           0.53 (0.33, 0.86)           0.83 (0.68, 1.02)   0.82 (0.69, 0.97)       Ref       1.04 (0.83, 1.30)  0.001
  **ER−**                                                                                                                                                            
  No. of cases                                                      14/13 106                   25/54 537           55/94 491       73/130 102        21/32 387       
  Multivariate RR[a](#t3-fn2){ref-type="fn"} (95% CI)           2.12 (1.18, 3.82)           0.84 (0.53, 1.33)   1.02 (0.72, 1.45)       Ref       1.17 (0.72, 1.91)  0.65
  **PR+**                                                                                                                                                            
  No. of cases/person-years                                         17/13 101                  103/54 526          182/94 448       307/130 040       86/32 368       
  Multivariate RR[a](#t3-fn2){ref-type="fn"} (95% CI)           0.62 (0.38, 1.02)           0.85 (0.68, 1.07)   0.83 (0.69, 1.00)       Ref       1.12 (0.88, 1.42)  0.003
  **PR−**                                                                                                                                                            
  No. of cases                                                      14/13 101                   42/54 526           82/94 448       128/130 040       28/32 368       
  Multivariate RR[a](#t3-fn2){ref-type="fn"} (95% CI)           1.21 (0.69, 2.12)           0.81 (0.57, 1.15)   0.89 (0.67, 1.18)       Ref       0.89 (0.59, 1.35)  0.73
  **ER+PR+**                                                                                                                                                         
  No. of cases/person-years                                         14/13 101                   98/54 519          171/94 438       292/130 024       80/32 357       
  Multivariate RR[a](#t3-fn2){ref-type="fn"} (95% CI)           0.54 (0.31, 0.93)           0.86 (0.68, 1.08)   0.82 (0.68, 1.00)       Ref       1.10 (0.85, 1.41)  0.003
  **ER−PR−**                                                                                                                                                         
  No. of cases                                                      11/13 101                   18/54 519           43/94 438       58/130 024        17/32 357       
  Multivariate RR[a](#t3-fn2){ref-type="fn"} (95% CI)           2.07 (1.07, 4.02)           0.77 (0.45, 1.30)   1.03 (0.69, 1.52)       Ref       1.19 (0.69, 2.04)  0.89

Abbreviations: CI=confidence interval; ER=oestrogen receptor; PR=progesterone receptor; RR=relative risk.

Adjusted for age (continuous), race (black, white, other), education (less than high school, high school graduate, some college, college or higher), marital status (married, unmarried), body-mass index (\<18.5, 18.5 -- 24.9, 25 -- 29.9, 30+ kg m^−2^), vigorous physical activity (\<1, 1 -- \<2, 2+ hours per day), smoking status (former, current, never smoker), pack-year (0, \>0 -- 20, \>20 -- 40, \>40), year since quitting (never smoker, current smoker, 0.5 -- 4, 5 -- 9, 10+ years), age at first live birth (\<20, 20 -- 29, 30+ years), number of live birth (0, 1 -- 2, 2+), age at menarche (12 or younger, older than 12), menopause (yes, no), use of hormonal replacement therapy (yes, no), use of multivitamin (yes, no), history of diabetes (yes, no), family history of cancer (no history, breast or ovarian cancer, other cancer) and alcohol consumption (never drinker, 0 -- 6, 7 -- 15, 16+ g per day).
